GGrantIndex
← Leaderboards

Shelley Deanne Miyamoto

University Of Colorado Denver

$5,520,361
Attributed
$11,496,079
Total exposure
6
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY200925
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,496,079 · 6

By mechanism

R01$9,940,898 · 3
R21$846,274 · 2
UM1$708,907 · 1

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Childhood

Research focus

ChildhoodAdultHeartHeart FailureVentricularHeart TransplantationResponseNew Therapeutic TargetClinical TrialsMyocardiumCommon VentricleSingle Ventricle Congenital Heart DiseaseAnimal ModelMyocardialCardiacMediatingSignal TransductionProspectiveGuidelinesOperative Surgical ProceduresPressureSerumNational Heart, Lung, And Blood InstituteChronic

Grant awards (26)

Targeting Mitochondria in Single Ventricle Heart Disease$650,943
R01 · FY2025 · HL · contact PI
Pediatric Heart Network - GATHER - between Washington University in St Louis and Children's Hospital Colorado$347,546
UM1 · FY2025 · HL
Targeting Mitochondria in Single Ventricle Heart Disease$651,604
R01 · FY2024 · HL · contact PI
Pediatric Heart Network - GATHER - between Washington University in St Louis and Children's Hospital Colorado$361,361
UM1 · FY2024 · HL
Targeting Mitochondria in Single Ventricle Heart Disease$87,104
R01 · FY2024 · HL · contact PI
Targeting Mitochondria in Single Ventricle Heart Disease$675,629
R01 · FY2023 · HL · contact PI
Targeting Mitochondria in Single Ventricle Heart Disease$161,134
R01 · FY2023 · HL · contact PI
Targeting Mitochondria in Single Ventricle Heart Disease$686,049
R01 · FY2022 · HL · contact PI
Targeting Mitochondria in Single Ventricle Heart Disease$161,134
R01 · FY2022 · HL · contact PI
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$799,064
R01 · FY2021 · HL
Targeting Mitochondria in Single Ventricle Heart Disease$723,914
R01 · FY2021 · HL · contact PI
Targeting mitochondria in SV heart disease$76,211
R01 · FY2021 · HL · contact PI
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$800,404
R01 · FY2020 · HL
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$898,361
R01 · FY2019 · HL
Myocardial Effects of PDE5 Inhibition in Single Ventricle Heart Disease$579,358
R01 · FY2019 · HL · contact PI
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$795,301
R01 · FY2018 · HL
Myocardial Effects of PDE5 Inhibition in Single Ventricle Heart Disease$576,093
R01 · FY2018 · HL · contact PI
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$47,571
R01 · FY2018 · HL
Myocardial Effects of PDE5 Inhibition in Single Ventricle Heart Disease$491,787
R01 · FY2017 · HL · contact PI
Myocardial Effects of PDE5 Inhibition in Single Ventricle Heart Disease$77,528
R01 · FY2017 · HL · contact PI
Myocardial Effects of PDE5 Inhibition in Single Ventricle Heart Disease$491,787
R01 · FY2016 · HL · contact PI
Myocardial Effects of PDE5 Inhibition in Single Ventricle Heart Disease$509,922
R01 · FY2015 · HL · contact PI
The Role of Histone Deacytelases in Right Ventricular Adaptation in Hypoplastic L$189,132
R21 · FY2014 · HL · contact PI
The Role of Histone Deacytelases in Right Ventricular Adaptation in Hypoplastic L$244,586
R21 · FY2013 · HL · contact PI
Cardiac Beta-Adrenergic Adaptation in Pediatric Heart Failure$223,356
R21 · FY2010 · HL
Cardiac Beta-Adrenergic Adaptation in Pediatric Heart Failure$189,200
R21 · FY2009 · HL